Development of monoclonal antibodies to prevent and treat infections from Flaviviruses
eu HORIZON-HLTH-2027-01-DISEASE-06 · Horizon Europe (HORIZON)
| Status | forthcoming |
|---|---|
| Opens | 10 Feb 2027 |
| Deadline | 13 Apr 2027 — 212 days |
| Action | HORIZON Research and Innovation Actions |
| Official page | https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunit… |
| Fetched | 2026-09-13 04:00:37+00:00 |
You are reading one call. 1,385 are open right now.
A search matches words. It cannot know what your institution works on. Give the name and every open call is ranked against it — this one included.
Free · no account · nothing stored that identifies youScope
Expected Outcome: This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to all the following expected outcomes: The scientific and clinical communities have a better understanding of and access to experimental monoclonal antibodies for the prevention and treatment of emerging or re-emerging viral infections, as well as for further clinical investigation. Candidate monoclonal antibody therapies are available to treat patients for emerging and re-emerging viral infections, increasing therapeutic options for clinical deployment in case of an epidemic or pandemic. Scope: Infectious diseases remain a major threat to health and health security in the EU and globally. Viral disease emergence is already being accelerated by climate change, and thus a proactive approach to the development of antiviral prophylactics and therapeutics in preparedness for future infectious disease outbreaks is needed. The capacity to produce antibodies that can target new variants and rapidly increase production would serve as an essential preparedness strategy against future health threats, whether from infectious disease epidemics or pandemics. This topic contributes to strengthening the Research and Innovation ecosystem within the EU and supports the implementation of the European Medical Countermeasures Strategy [1] . Applicants should explicitly state in their proposal which of the following Flaviviruses is targeted and the proposed work should address only this specific Flavivirus. The proposed work should aim to advance the development of existing prophylactic and therapeutic monoclonal antibody candidates targeting exclusively one of the following Flaviviriuses: Dengue Virus Tick-borne Encephalitis Virus Japanese Encephalitis Virus West Nile Fever Virus Yellow Fever Virus Zika Virus Proposals should focus on antibodies produced or derived from a single cell clone through recombinant expression, such as B-cell derived antibodies, hybridoma derived antibodies and nanobodies. Proposals should thus aim to diversify and accelerate the global prophylactic and therapeutic research and development portfolio for emerging and re-emerging viral infections, and to strengthen the leading role of the EU in prophylactic and therapeutic research and development. Proposals should address all the following research areas: If necessary, finalisation of …
What consortia for this call have looked like
5 projects
have been funded under this line
(HORIZON-HLTH-DISEASE-06) in Horizon Europe and H2020. This is what they
were made of — not a recommendation, just what the Commission signed.
range 9–12
24 seen across all of them
across those projects
The mix of organisations
Who coordinated them
Coordinating an EU project is a demanding, specific job. These organisations have done it on this topic line before.
This is the shape, not the consortium. It says how many partners these projects had and what kinds of organisation were in them. It does not know whether your idea needs the same mix, who is available, who is already committed elsewhere, or how the work and the budget should be divided. Those are judgement calls on a specific proposal, and no amount of public data answers them.
Building the actual consortium — finding the partners, agreeing the roles, and writing it so it survives an evaluation — is what Scientific Network Management does. Free either way; the radar does not change if you never ask.
Finding the call is the easy half. Scientific Network Management is the grant-writing practice behind this radar — 13 years of writing and managing EU-funded research projects, including two EuropeAid technical assistance contracts building biotechnology centres in Türkiye as Team Leader.
Talk to us What SNM does No obligation, and nothing here is conditional on using us — the radar stays free and complete either way.